Baidu
map

MedSci参加第二届T-reg和Th17细胞研究进展及其临床应用国际会议

2010-07-20 MedSci原创 MedSci原创

     2010年7月21日,第二届T-reg和Th17细胞研究进展及其临床应用国际会议于上海顺利落下帷幕。此次会议吸引了近千名海内外相关人士参加,并就相关问题进行了深入交流和讨论。      本次会议的演讲者大多是国际该领域的顶尖学者,大多来自牛津、哈佛、东京知名大学及国际著名研究所, 每一位学

2010年7月21日,第二届T-reg和Th17细胞研究进展及其临床应用国际会议于上海顺利落下帷幕。此次会议吸引了近千名海内外相关人士参加,并就相关问题进行了深入交流和讨论。 

本次会议的演讲者大多是国际该领域的顶尖学者,大多来自牛津、哈佛、东京知名大学及国际著名研究所, 每一位学者都带来了他们最新的研究成果,其中很多都未在国际期刊上发表,现场讨论热烈。 本次会议还特邀国际著名期刊Nature Immunology的资深编辑Dr Laurie A. Dempsey,Immunity主编Dr Peter Lee、Journal of Clinical Investigation主编Dr Larry Turka、cell research的主编来到现场,向听众讲解各个期刊的发展历史及各位学者投稿的注意事项。

曹雪涛教授在会上讲座

各位专家热烈讨论

MedSci工作人员与Nature Immunology资深编辑Dr. Laurie A. Dempsey

MedSci工作人员与Immunity主编 Dr. Peter Lee

特别值得一提的是国内最成功的学术期刊—Cell Research,05年至08年Cell Research的影响因子分别:1.936,2.161,3.426,4.217,4.535 今年又飙升到8.151。Cell Research的创刊主编姚錱院士在创刊时就确定了国际化的办刊方向,十年呕心沥血,为期刊的发展打下了结实的基础。2006年新的主编队伍接任后(主编为裴钢院士,并从海外引进时任Cell 杂志Associate editor的李党生博士担任常务副主编),继续大力推进Cell Research国际化办刊思想和目标,锐意改革,大胆创新,为期刊快速发展带来新的机遇。近几年来,Cell Research发表了一系列高质量优秀论文并迅速引起国际反响,已逐步成为我国和国际科学家优秀科研成果的一 重要传播发布平台。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇,真牛,可惜没机会参加这样的高端会议,我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
    2016-10-10 童小孩

    好厉害

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇,真牛,可惜没机会参加这样的高端会议,我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇,真牛,可惜没机会参加这样的高端会议,我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇,真牛,可惜没机会参加这样的高端会议,我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇,真牛,可惜没机会参加这样的高端会议,我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
    2010-07-22 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇,真牛,可惜没机会参加这样的高端会议,我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇,真牛,可惜没机会参加这样的高端会议,我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
    2010-07-20 doctor

    哇,真牛,可惜没机会参加这样的高端会议,我也是做免疫的呢

    0

相关资讯

MedSci参加《数字脑与脑功能开发学术研讨会》

2010年6月25日,由上海市人民政府、中国科学院和中国工程院主办,复旦大学附属华山医院承办的《东方科技论坛——数字脑与脑功能开发学术研讨会》于上海国际会议中心圆满落下帷幕。 这次会议邀请了国内外脑外科知名专家与学者共同探讨了中国与欧美发达国家在数字脑与脑功能开发领域现在所存在的差距,并且讨论了中国要与国外发达国家看其需

MedSci开通期刊排名和期刊热度排名查询

    什么样的期刊是国际顶级期刊?什么期刊比较火?这是大家关心的话题。象前阵子,在MedSci网站上争论PLOS ONE是不是“牛”期刊。支持者认为PLOS ONE在综合类期刊中,排名居第四位,见 //www.sandwebs.com/sci/top10if.do?s=综合性期刊 ,但说不牛的,是因为它目前只有4分,与Nature, Science, PNAS差

MedSci科室讲座——浙大附一心血管内科

        2010年7月1日,MedSci于浙江大学医学院附属第一医院做了题为《SCI论文写作技巧》的交流会,交流会围绕心血管内科近年来的学术发展趋势,就该领域主要学术期刊影响因子变化趋势、期刊在国内的影响力以及在发表这类SCI文章常见的问题等几个方面与与会老师及同学做了深入的交流及探讨。 MedSci李老师

MedSci参加第一届中国分子诊断技术大会

2010年6月22日,第一届中国分子诊断技术大会于北京新世纪日航饭店隆重开幕,期间来自海内外的近600位专家学者参与了这次学术盛会。 本次会议由中国工程院医药卫生部、中国医师协会检验医师分会、中华医学院检验分会、中国生物芯片标准化技术委员会、清华大学医学院等共同主办。并得到罗氏、凯杰、博奥、安捷伦、GE、Life Tec

MedSci开通中国学者研究动态栏目

    为了更好展示中国学者的临床和科研学术水平,同时也为广大一线临床和科研工作者提供参照。特别从Pubmed等公开数据库中,筛选出以中国学者为主的,近年来发表的代表性论文,并提供摘要(当然还附带机器翻译,仅供参考)。     这些论文比较具有代表性,许多学者研究的领域,恰正是我们大家正从事的领域,具有参考价值。这些摘要,从文

MedSci参加第二届上海东方呼吸病国际论坛

2010年6月27日,由第二军医大学主办的“第2届上海东方呼吸病国际论坛”于上海浦东国际会议中心落下帷幕。此次论坛吸引到近2000名国内外相关人士参加,并就相关问题进行了深入交流和讨论。 此次会议以"着力提高我国呼吸内科专科医师临床诊治水平"为宗旨秉承第一届论坛确立的"传承、交流与合作"这一主题。本次论坛不仅

Baidu
map
Baidu
map
Baidu
map